<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485209</url>
  </required_header>
  <id_info>
    <org_study_id>SGNTV-001</org_study_id>
    <secondary_id>2017-005076-26</secondary_id>
    <nct_id>NCT03485209</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors</brief_title>
  <acronym>innovaTV 207</acronym>
  <official_title>Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study tisotumab vedotin to find out whether it is an effective treatment for&#xD;
      certain solid tumors and what side effects (unwanted effects) may occur. There are three&#xD;
      parts to this study. In Part A, the treatment will be given to participants every 3 weeks&#xD;
      (3-week cycles). In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15&#xD;
      every 4-week cycle. In Part C, participants may receive tisotumab vedotin on Days 1 and 15 or&#xD;
      Days 1, 8, and 15 on a 4-week cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this trial is to assess the activity, safety, and tolerability of&#xD;
      tisotumab vedotin for the treatment of selected solid tumors. Patients will be treated with&#xD;
      single agent tisotumab vedotin. Patients who meet eligibility criteria will be enrolled into&#xD;
      cohorts based on tumor type. Tumor types to be evaluated include colorectal cancer, squamous&#xD;
      non-small cell lung cancer (NSCLC), exocrine pancreatic adenocarcinoma, and squamous cell&#xD;
      carcinoma of the head and neck (SCCHN).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Type, severity, and relatedness of adverse events. An AE is any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed and Unconfirmed ORR</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Proportion of patients who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Proportion of patients who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator, or meet the SD criteria at least once after start of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Time from the first documentation of objective response to the first documentation of PD or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Time from the start of study treatment to the first documentation of objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>Time from the start of study treatment to date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Through 8 days after dosing</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>Through 8 days after dosing</time_frame>
    <description>Observed plasma concentration at the end of the dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ATAs</measure>
    <time_frame>Through 8 days after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Exocrine Pancreatic Cancer</condition>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Tisotumab Vedotin - Q3W Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tisotumab Vedotin every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tisotumab Vedotin - 3Q4W Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tisotumab Vedotin on Days 1, 8, and 15 of 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tisotumab Vedotin - 3Q4W/2Q4W Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tisotumab Vedotin on Days 1, 8, and 15 of a 28-day cycle and Tisotumab Vedotin on Days 1 and 15 of every 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tisotumab vedotin</intervention_name>
    <description>Given into the vein (IV; intravenously)</description>
    <arm_group_label>Tisotumab Vedotin - 3Q4W Schedule</arm_group_label>
    <arm_group_label>Tisotumab Vedotin - 3Q4W/2Q4W Schedule</arm_group_label>
    <arm_group_label>Tisotumab Vedotin - Q3W Schedule</arm_group_label>
    <other_name>TIVDAK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed, locally-advanced or metastatic colorectal or pancreatic cancer, squamous&#xD;
             NSCLC, or SCCHN patients who are not candidates for standard therapy.&#xD;
&#xD;
          -  All patients must have experienced disease progression on or after their most recent&#xD;
             systemic therapy.&#xD;
&#xD;
          -  Baseline measurable disease as measured by RECIST v1. 1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.&#xD;
&#xD;
          -  Colorectal cancer patients must have received prior therapy with each of following&#xD;
             agents, if eligible: a fluoropyrimidine, oxaliplatin, irinotecan, and/or bevacizumab.&#xD;
             Patients should have received no more than 3 systemic regimens in the metastatic&#xD;
             setting.&#xD;
&#xD;
          -  Patients with NSCLC must have predominant squamous histology. Patients must have&#xD;
             received prior therapy with a platinum-based treatment and a checkpoint inhibitor&#xD;
             (CPI), if eligible. Patients should have received no more than 2 systemic regimens in&#xD;
             the metastatic setting.&#xD;
&#xD;
               -  Patients eligible for a tyrosine kinase inhibitor should have received such&#xD;
                  therapy. These patients should have received no more than 3 systemic regimens in&#xD;
                  the metastatic setting.&#xD;
&#xD;
          -  Patients with exocrine pancreatic adenocarcinoma must have predominant adenocarcinoma&#xD;
             histology. Patients must have received prior therapy with a gemcitabine-based or&#xD;
             5FU-based regimen, if eligible, and should have received no more than 1 systemic&#xD;
             regimen in the unresectable or metastatic setting.&#xD;
&#xD;
          -  Patients with SCCHN must have received prior therapy with a platinum-based regimen and&#xD;
             a checkpoint inhibitor (CPI), if eligible, and should have received no more than 3&#xD;
             systemic regimens in the recurrent/metastatic setting.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active bleeding conditions&#xD;
&#xD;
          -  Ocular surface disease at the time of enrollment (Note: cataract is not considered&#xD;
             active ocular surface disease for this protocol)&#xD;
&#xD;
          -  Pulmonary disease requiring chronic medical therapy, unrelated to underlying cancer&#xD;
&#xD;
          -  Uncontrolled tumor-related pain&#xD;
&#xD;
          -  Peripheral neuropathy greater than or equal to Grade 2&#xD;
&#xD;
          -  History of another malignancy within 3 years of the first dose of study drug, or any&#xD;
             evidence of residual disease from a previously diagnosed malignancy.&#xD;
&#xD;
          -  Active brain metastasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Beca, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>8663337436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Ardunio</last_name>
      <phone>916-734-8512</phone>
      <email>earduino@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christina Devisser</last_name>
      <phone>916-734-1787</phone>
      <email>cdevisser@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>May Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan W Riess</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center / Blood and Marrow Transplant Program</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Hann</last_name>
      <phone>408-426-4900</phone>
      <email>amoffat@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Omid S Tehrani</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Wakelee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Health System (PVHS)</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Saller</last_name>
      <phone>970-297-6150</phone>
    </contact>
    <investigator>
      <last_name>Steven R Schuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Wiess</last_name>
      <phone>203-737-5312</phone>
      <email>christina.wiess@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Jill Lacy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shands Cancer Center / University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashton Monismith</last_name>
      <phone>352-265-0680</phone>
      <email>amonismith@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ingalls Cancer Care / Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Marriott</last_name>
      <phone>708-339-4800</phone>
      <email>mmarriott@ingalls.org</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Kruczek</last_name>
      <phone>708-339-4800</phone>
      <email>kkruczek@ingalls.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kimberly R Kruczek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danielle Sterrenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Truesdale</last_name>
      <phone>913-588-6029</phone>
      <email>mhintz@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Anwaar Saeed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine C Conway</last_name>
      <phone>502-629-4267</phone>
      <email>catherine.conway@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>John Hamm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Wolanski</last_name>
      <phone>617-632-6623</phone>
      <email>awolanski@partners.org</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HealthPartners Institute</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alissa Gavenda</last_name>
      <phone>952-993-6071</phone>
      <email>Alissa.Gavenda@ParkNicollet.com</email>
    </contact>
    <investigator>
      <last_name>Daniel M Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center / University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Garbarino</last_name>
      <phone>919-445-4187</phone>
      <email>jennifer_garbarino@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Juneko Grilley-Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center / Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Averill</last_name>
      <phone>336-713-7748</phone>
      <email>saverill@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Thomas</last_name>
      <phone>336-716-2011</phone>
      <email>jethomas@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lowell L Hart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Moher</last_name>
      <phone>503-494-3606</phone>
      <email>moher@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacqueline Vuky</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shivaani Kummar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Vatkevich</last_name>
      <phone>401-444-6217</phone>
      <email>John.vatkevich@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Howard Safran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meiyue Hong</last_name>
      <phone>713-745-4367</phone>
      <email>mghong@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>David S Hong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jane Flores</last_name>
      <phone>806-725-7993</phone>
      <email>maryjane.Flores@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Isaac Tafur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Mouton</last_name>
      <phone>713-703-2398</phone>
      <email>Alice.mouton@renovatioclinical.com</email>
    </contact>
    <investigator>
      <last_name>Mary Crow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sallie Mannen</last_name>
      <phone>434-297-5724</phone>
      <email>SBM8QZ@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Reilley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta / Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jennifer Spratlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospitalier Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <state>Other</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Christophe Borg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre léon Bérard</name>
      <address>
        <city>LYON cedex 08</city>
        <state>Other</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Jerome Fayette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM Hôpital Nord</name>
      <address>
        <city>Marseille Cedex 20</city>
        <state>Other</state>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Sebastien Salas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruhr-Uni. Bochum, St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <state>Other</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Anke Reinacher-Schick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vincentius-Diakonissen-Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <state>Other</state>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Christian Meyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seconda Università degli Studi di Napoli, AOU</name>
      <address>
        <city>Napoli</city>
        <state>Other</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Fortunato Ciardiello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica, Ospedale Civile S. Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <state>Other</state>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Federico Cappuzzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Casanova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PU Campus Bio-medico di Roma</name>
      <address>
        <city>Roma</city>
        <state>Other</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tonini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Other</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>José Luis Manzano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Quirónsalud Barcelona Instituto Oncologico Baselga</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Alejandro Martínez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Analia Azaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enriqueta Felip Font</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Teresa Alonso Gordoa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HM Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Cubillo Gracian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guys And St Thomas Hospital</name>
      <address>
        <city>London</city>
        <state>Other</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>James Spicer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>SCCHN</keyword>
  <keyword>CRC</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Head and neck cancer</keyword>
  <keyword>Seattle Genetics</keyword>
  <keyword>HNSCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tisotumab vedotin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

